Diagnosis and management of Barrett's oesophagus

BMJ (Online)

Volumn 341, Issue 7773, 2010, Pages 597-602

  Jankowski, Janusz ^a,b,c   Barr, Hugh ^d,e   Wang, Ken ^f   Delaney, Brendan ^g  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^d CRANFIELD UNIVERSITY   (United Kingdom)

^e GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^f MAYO CLINIC   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ABLATION THERAPY; ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; CANCER RISK; CLINICAL TRIAL; DISEASE COURSE; DISEASE MANAGEMENT; ENDOSCOPIC SURGERY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS RESECTION; HUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; STOMACH FUNDOPLICATION; SUPPORT GROUP;

ADENOCARCINOMA; ADULT; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; FEMALE; FORECASTING; FUNDOPLICATION; GASTROSCOPY; HUMANS; MALE; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 77956830345     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c4551     Document Type: Review

References (35)

1. Shaheen NJ, Richter JE. Barrett's oesophagus. Lancet 2009;373:850-61.
2. Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK. History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology 2010;138:854-69.
3. Jankowski J, Harrison RF, Perry I, Balkwill F, Tselepis C. Seminar: Barrett's metaplasia. Lancet 2000;356:2079-85.
4. Barrett's Dysplasia and Cancer Taskforce 'BAD CAT' consensus group. International consensus of the management of dysplastic Barrett's and cancer. World Gastroenterology Organisation. http://www.worldgastroenterology.org/ international-consensus-of-management-of-dysplastic-barretts-and-cancer.html.
5. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet 2006;367:2086-100.
6. Ronkainen J, Pertti A, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31. (Pubitemid 41772961)
7. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R for the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20.
8. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West. Gastroenterology 2002;122:588-90. (Pubitemid 34117010)
9. Peng S, Cui Y, Xiao YL, Xiong LS, Hu PJ, Li CJ, et al. Prevalence of erosive esophagitis and Barrett's esophagus in the adult Chinese population. Endoscopy 2009;41:1011-7.
10. Gerson LB, Banerjee S. Screening for Barrett's esophagus in asymptomatic women. Gastrointest Endosc 2009;70:867-73.
11. Moayyedi P, Burch N, Akhtar-Danesh N, Enaganti SK, Harrison R, Talley NJ, et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2008;27:316-20.
12. Jankowski J, Wright NA, Meltzer S, Triadafilopoulos G, Geboes K, Casson A, et al. Molecular evolution of the metaplasia dysplasia adenocarcinoma sequence in the esophagus (MCS). Am J Pathol 1999;154:965-74.
13. Robertson EV, Jankowski JA. Genetics of gastroesophageal cancer: paradigms, paradoxes and prognostic utility. Am J Gastroenterol 2008;103:443-9.
14. Jankowski J, Odze R. Biomarkers in gastroenterology; between hype and hope comes histopathology. Am J Gastroenterol 2009;104:1093-6.
15. National Institute for Health and Clinical Excellence. Dyspepsia: managing dyspepsia in adults in primary care (clinical guideline CG17). NICE, 2005.
16. Sharma P, Dent J, Armstrong D, Bergman J, Gossner L, Hoshihara Y, et al. The development and validation of an endoscopic grading system for Barrett's esophagus - the Prague C and M criteria. Gastroenterology 2006;131:1392-9.
17. Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, et al. A critical review of the diagnosis and management of Barrett's esophagus. Gastroenterology 2004;127:310-30.
18. Wong T, Tian J, Nagar AB. Barrett's surveillance identifies patients with early esophageal adenocarcinoma. Am J Med 2010;123:462-7.
19. Rubenstein JH, Sonnenberg A, Davis J, McMahon L, Inadomi JM. Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc 2008;68:849-55.
20. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277-88.
21. British Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. BSG, 2005.
22. Das D, Ishaq S, Harrison R, Kosuri K, Harper E, deCaestecker J, et al. Management of Barrett's oesophagus in the UK: over treated, and under biopsied but improved by a national randomised trial. Am J Gastroenterol 2008;103:1079-89.
23. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97.
24. Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009;136:2101-14.
25. Cook MB, Wild CP, Everett SM, Hardie LJ, Bani-Hani KE, Martin IG, et al. Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2007;16:2090-6.
26. National Institute for Health and Clinical Excellence. Ablative therapy for the treatment of Barrett's oesophagus (clinical guideline CG106). NICE, 2010.
27. Epstein D, Bojke L, Sculpher MJ for the REFLUX trial group. Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. BMJ 2009;339:b2576.
28. Obszynska J, Atherfold P, Nanji M, Glancy D, Santander S, Graham T, et al. Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo. Gut 2010;59:156-63.
29. Leedham S, Jankowski J. The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus: the good, the bad and the flawed. Am J Gastroenterol 2007;102:21-3. (Pubitemid 46072038)
30. Leedham SJ, Preston SL, McDonald SAC, Elia G, Bhandari P, Poller D, et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 2008;57:1041-8.
31. Tselepis C, Perry I, Dawson C, Hardy R, Darnton J, McConkey C, et al. Tumour necrosis factor alpha in Barrett's metaplasia: a novel mechanism of action. Oncogene 2002;39:6071-81.
32. Das D, Chilton A, Jankowski J. Oesophageal cancer prevention and the AspECT trial. In: Senn HJ, Kapp U, Otto F eds. Cancer Prevention II. Springer, 2009. pp 161-72.
33. Overholt BF, Wang KK, Burdick JS, Lightdale CJ, Kimmey M, Nava HR, et al for the International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007;66:460-8.
34. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Haringsma J, van de Vrie W, et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut 2004;53:785-90.
35. Fight Oesophageal Reflux Together (FORT). http://refluxhelp.org/.